Chau Dang, MD; Hao Guo, MS; Julie Najita, PhD; et al.
free access
JAMA Oncol. 2016;2(1):29-36. doi:10.1001/jamaoncol.2015.3709
This phase II cohort study examined the cardiac safety of paclitaxel and trastuzumab in patients with node-negative, ERBB2-positive breast cancer and found that the cardiac toxic effects were low, suggesting that left ventricular ejection fraction monitoring could be simplified for many patients.
-
Editorial
Trastuzumab and Cardiac Outcomes in Breast Cancer: A Story We Know by Heart?
Gérard Milano, PhD; Emmanuel Chamorey, PharmD, PhD; Jean-Marc Ferrero, MD, PhD
JAMA Oncol
Shanwu Gao, MSc; Chabane Tibiche, MSc; Jinfeng Zou, PhD; et al.
free access
JAMA Oncol. 2016;2(1):37-45. doi:10.1001/jamaoncol.2015.3413
This genetic database analysis of stage II colon cancer samples finds that certain gene signature sets may serve as prognostic predictors and facilitate the identification of patients who could gain survival benefit from fluorouracil adjuvant chemotherapy.
Joseph McLaughlin, MD; Gang Han, PhD; Kurt A. Schalper, MD, PhD; et al.
free access
JAMA Oncol. 2016;2(1):46-54. doi:10.1001/jamaoncol.2015.3638
This study uses rabbit monoclonal antibodies to demonstrate PD-L1 protein expression in human non鈥搒mall-cell lung cancer biopsy specimens and found heterogeneity within tumors and interassay discordance.
Edith A. Perez, MD; Karla V. Ballman, PhD; Kathy S. Tenner, BS; et al.
free access
JAMA Oncol. 2016;2(1):56-64. doi:10.1001/jamaoncol.2015.3239
This exploratory analysis of data from the N9831 trial evaluated the association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in women with human epidermal growth factor receptor 2 (HER2)鈥損ositive breast cancer treated with chemotherapy or chemotherapy plus trastuzumab.
Rodrigo R. Munhoz, MD; Allan A. L. Pereira, MD; André D. Sasse, MD; et al.
free access
JAMA Oncol. 2016;2(1):65-73. doi:10.1001/jamaoncol.2015.3251
This systematic review and meta-analysis provides evidence suggesting that gonadotropin-releasing hormone agonists given concurrently with chemotherapy to premenopausal patients undergoing treatment for early-stage breast cancer is associated with prevention of early menopause.
Mark G. Shrime, MD, MPH, PhD; Bart S. Ferket, MD, PhD; Daniel J. Scott, PhD; et al.
free access
JAMA Oncol. 2016;2(1):76-83. doi:10.1001/jamaoncol.2015.3336
This decision analysis study investigated the optimal duration of time-limited trials of intensive care among critically ill patients with cancer.
Marianne Schmid, MD; Christian P. Meyer, MD; Gally Reznor, MS; et al.
free access
JAMA Oncol. 2016;2(1):85-93. doi:10.1001/jamaoncol.2015.3384
This study of a SEER-Medicare linked database found that black men treated with radical prostatectomy for prostate cancer are more likely to experience adverse events and incur higher costs compared with non-Hispanic white men, but this does not translate into a difference in mortality.
-
Invited Commentary
The Meaning of Race in Prostate Cancer Treatment
Otis W. Brawley, MD, MACP
JAMA Oncol
Lane L. Frasier, MD; Sara Holden, MD; Timothy Holden, MD, MS; et al.
free access
JAMA Oncol. 2016;2(1):95-101. doi:10.1001/jamaoncol.2015.3717
This study of SEER data on women with stage I to III breast cancer undergoing mastectomy investigated whether changes in National Comprehensive Cancer Network guidelines have increased use of postmastectomy radiation therapy and affected receipt of breast reconstruction.
Kasmintan A. Schrader, MBBS, PhD, FRCPC, DABMG; Donavan T. Cheng, PhD; Vijai Joseph, PhD; et al.
free access
JAMA Oncol. 2016;2(1):104-111. doi:10.1001/jamaoncol.2015.5208
This large case series found that germline variants were common in individuals with advanced cancer who underwent tumor-normal genetic sequencing, which may prove useful in revealing otherwise unsuspected syndromic associations.
Sumant Inamdar, MD; Eoin Slattery, MD; Ramandeep Bhalla, MD; et al.
free access
JAMA Oncol. 2016;2(1):112-117. doi:10.1001/jamaoncol.2015.3670
This cohort study uses National Inpatient Sample database data to compare the incidence of procedure-related adverse events with endoscopic vs percutaneous drainage of malignant biliary tract obstruction..